Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence.

de la Rosa, David; Martínez-Garcia, Miguel-Angel; Olveira, Casilda; Girón, Rosa; Máiz, Luis; Prados, Concepción

de la Rosa, David; Martínez-Garcia, Miguel-Angel; Olveira, Casilda; Girón, Rosa; Máiz, Luis; Prados, Concepción.

Afiliação

de la Rosa D; 1 Pneumology Unit, Hospital Plató, Barcelona, Spain.
Martínez-Garcia MA; 2 Pneumology Department, Hospital Universitario y Politécnico La Fe, València, Spain.
Olveira C; 3 Pneumology Department, Hospital Regional Universitario de Málaga, Instituto de Biomedicina de Málaga (IBIMA), Universidad de Málaga. Málaga, Spain.
Girón R; 4 Pneumology Department, Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa, Madrid, Spain.
Máiz L; 5 Pneumology Department, Unidad de Bronquiectasias y Fibrosis Quística, Hospital Universitario Ramón y Cajal. Madrid, Spain.
Prados C; 6 Pneumology Department, Unidad de Bronquiectasias y Fibrosis Quística, Hospital Universitario La Paz, IDIPaz, Madrid, Spain.

Chron Respir Dis ; 13(4): 361-371, 2016 Nov.

Article em En | MEDLINE | ID: mdl-27072020

Palavras-chave

Pharmacoeconomics; Pseudomonas aeruginosa; antibacterial agents; bronchiectasis; disease exacerbation; inhalation drug administration

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Chron Respir Dis Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Espanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google